


Rethinking Type 1 Diabetes Care



Panelists

SONIA SIDHU

Member of Parliament,
Brampton South
Chair of the All-Party
Diabetes Caucus in the
Parliament

DR. BRUCE PERKINS

Endocrinologist and Director,
Leadership Sinai Centre for
Diabetes, University of
Toronto


JENNIFER BIZZARRI

Individual living with T1D
and Board Member, JDRF

Moderator

LARA GREEN

National Manager,
Research and Training
Programs at JDRF
Canada




Some people have
type 1 diabetes.

This means their
pancreas doesn't
produce insulin.



A Simplified View of Management Tasks for Type 1 Diabetes


Healthy Lifestyle Behaviour



Glucose Monitoring





Intensive Insulin Therapy



Management of Hypoglycemia and Hyperglycemia/Ketones



Multiprofessional Care Team Visits, Laboratory Visits, and Complications Screening Visits



CURRENT STATE OF AFFAIRS IN THE U.S. AND CANADA


Relationship of HbA1c (a measure of average blood sugar levels) with Age



Also, Severe “Diabetic Ketoacidosis” at T1D onset is Prevalent and it worsened during the pandemic

In children prevalence 36% prior to and 55% during the pandemic

Sellers et al. Ped & Child Health 2021; Meehan et al Ped Diabet 2015




Nicole Foster et al. T1D Exchange. DT&T 2019


Kellee M. Miller et al. Diabetes Care 2015; Wood et al. T1D Exchange Clinic Network. Diabetes Care 2013

Alanna Weisman et al. Can J Diab 2024


T1D Progresses in 3 Stages: Allows the possibility of PREDICTION




With ≥ 2 T1D Autoantibodies, Progression to Stage 3 Clinical T1D is Almost Certain (regardless of family history)




T1D Diagnosis in Childhood has a Negative Survival Impact



A better transition into T1D onset and improvements in early management are expected to translate into improved survival



The TRIALNET Pathway to Prevention Study Process



The Screening Test Options

General Population

vs.

Those with Family History T1D or autoimmune conditions (like celiac disease or hypothyroidism)

[Genetic Risk Score (GRS)]

Antibody Levels (GAD, ICA, IA-2, ZnT8, IAA)

Measures of Glucose Level (Home fingerstick testing, OGTT, A1c, FBS, CGM)





What is TrialNet?


TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research.

They offer risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression.

Who is eligible?

This screening kit is available to family members of individuals with T1D

- Immediate relatives (parents, siblings, children) of someone with T1D, age 2.5-45
- Other relatives (grandchildren, nieces/nephews, cousins) of someone with T1D, age 2.5-20
- To sign up for a screening kit:
<https://www.diabetestrialnet.org/webapp/PreRegTracking/OnlineScreening.aspx>
- You will be given an at-home test-kit that can be done with a finger stick or go to a local lab for a blood draw
- The kit is available anywhere in Canada at zero cost to participants



T1D Screening Program Engages Patient Partners

By kristalamb Posted date: September 26, 2023

CanScreenT1D is a new project led by Diabetes Action Canada collaborator, Dr. Diane Wherrett, who is a Pediatric Endocrinologist at The Hospital for Sick Children in Toronto. The program is a national consortium that will explore screening for type 1 diabetes (T1D) in Canada.

This summer, CanScreenT1D received \$12 million in funding from the CIHR-JDRF Type 1 Diabetes Screening Research Consortium Team Grant


Featured in Article



Diane Wherrett

[View Profile](#)

Rethinking Type 1 Diabetes Care



Panelists

SONIA SIDHU

Member of Parliament,
Brampton South
Chair of the All-Party
Diabetes Caucus in the
Parliament

DR. BRUCE PERKINS

Endocrinologist and Director,
Leadership Sinai Centre for
Diabetes, University of
Toronto

JENNIFER BIZZARRI

Individual living with T1D
and Board Member, JDRF

Moderator

LARA GREEN

National Manager,
Research and Training
Programs at JDRF
Canada

TIMELINE

NATIONAL DIABETES FRAMEWORK + FREE DIABETES MEDICATION FOR CANADIANS



2020

MP Sidhu introduces Bill C-237, An Act to Establish a National Framework for Diabetes in Parliament.



2022

Government of Canada releases Framework for Diabetes in Canada.



2017

MP Sidhu calls for Health Committee to do a study on Diabetes and holds Canada-wide consultations with Diabetes experts.



2021


Bill C-237 passes in the parliament and receives Royal Assent.



2024

Pharmacare to help more than 3.5 million Canadians living with Diabetes get medication and resources.

Rethinking Type 1 Diabetes Care



Panelists

SONIA SIDHU

Member of Parliament,
Brampton South
Chair of the All-Party
Diabetes Caucus in the
Parliament

DR. BRUCE PERKINS

Endocrinologist and Director,
Leadership Sinai Centre for
Diabetes, University of
Toronto

JENNIFER BIZZARRI

Individual living with T1D
and Board Member, JDRF

Moderator

LARA GREEN

National Manager,
Research and Training
Programs at JDRF
Canada